Shares of RegeneRx Biopharmaceuticals Inc. (OTCMKTS:RGRX – Get Free Report) passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $0.01 and traded as high as $0.1730. RegeneRx Biopharmaceuticals shares last traded at $0.1730, with a volume of 50 shares.
RegeneRx Biopharmaceuticals Price Performance
The stock has a 50 day simple moving average of $0.01 and a 200-day simple moving average of $0.01.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc is a biotechnology company focused on developing regenerative therapies based on thymosin beta 4, a naturally occurring peptide involved in tissue repair, cell migration and inflammation regulation. The company’s research has primarily targeted conditions affecting the eye and other tissues.
RegeneRx’s lead product candidate, RGN-259, is a topical ophthalmic formulation of thymosin beta 4 under development for ocular surface disorders, including neurotrophic keratopathy and dry-eye-related conditions.
Read More
- Five stocks we like better than RegeneRx Biopharmaceuticals
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
